Given the patient’s relatively advanced age at onset compared with previously reported cases, the tumor's aggressive growth, and the limited genomic data available for IMTs beyond ALK alterations, we performed WES to investigate potential novel genetic drivers of tumor progression. This evidence concerns the gene ALK and neoplasm.